Translating Institutional Science into Commercial Reality

November 18, 2020 12:00 PM - 1:00 PM

Webinar, click "live-stream" button to view

Add to Calendar 11/18/2020 12:00:43 PM 11/18/2020 1:00:43 PM Translating Institutional Science into Commercial Reality In this forum, an expert roundtable will discuss the challenges and triumphs of translating science generated within large area educational/research institutions into commercial and therapeutic reality. Achieving this goal requires meeting the unique challenges involved in satisfying the sometimes divergent institutional and commercial interests of the key players involved. The panel will attempt to shed light on these issues that persist in our biotechnology ecosystem. 

Those looking to better understand the intricacies and legal processes associated with working with tech transfer offices, academic/industry collaborations, or engaging with large pharma should attend. 

MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.
Webinar, click "live-stream" button to view
Senior Associate Director for Technology Transactions, Office of Technology Development, Harvard
Kat Holliday is Senior Associate Director for Technology Transactions in Harvard’s Office of Technology Development where her responsibilities include negotiating license and equity agreements for start-up companies forming around Harvard innovations, including those developed at Harvard Medical School, the Harvard Faculty of Arts and Sciences, the Harvard John A. Paulson School of Engineering and Applied Sciences and the Harvard T.H. Chan School of Public Health. Prior to OTD, Kat represented VionX Energy Corporation, a flow-battery, energy storage portfolio company of VantagePoint Capital Partners and Starwood Energy Group. She was previously a senior attorney in both the life sciences and clean energy practice groups at Mintz Levin in Boston, representing venture-backed companies and investors. She is a graduate of Harvard College and Harvard Law School.